Logo image of SKIN

BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

NASDAQ:SKIN - Nasdaq - US88331L1089 - Common Stock - Currency: USD

1.61  +0.15 (+10.27%)

After market: 1.64 +0.03 (+1.86%)

Fundamental Rating

3

Overall SKIN gets a fundamental rating of 3 out of 10. We evaluated SKIN against 35 industry peers in the Personal Care Products industry. While SKIN seems to be doing ok healthwise, there are quite some concerns on its profitability. SKIN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SKIN has reported negative net income.
SKIN had a positive operating cash flow in the past year.
SKIN had negative earnings in 4 of the past 5 years.
In multiple years SKIN reported negative operating cash flow during the last 5 years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -5.72%, SKIN is doing worse than 74.29% of the companies in the same industry.
The Return On Equity of SKIN (-83.62%) is worse than 68.57% of its industry peers.
Industry RankSector Rank
ROA -5.72%
ROE -83.62%
ROIC N/A
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

SKIN has a Gross Margin of 62.52%. This is comparable to the rest of the industry: SKIN outperforms 48.57% of its industry peers.
In the last couple of years the Gross Margin of SKIN has declined.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SKIN has more shares outstanding than it did 1 year ago.
SKIN has a worse debt/assets ratio than last year.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.09, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
SKIN has a worse Altman-Z score (0.09) than 82.86% of its industry peers.
SKIN has a debt to FCF ratio of 18.53. This is a negative value and a sign of low solvency as SKIN would need 18.53 years to pay back of all of its debts.
SKIN has a Debt to FCF ratio (18.53) which is comparable to the rest of the industry.
SKIN has a Debt/Equity ratio of 12.01. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SKIN (12.01) is worse than 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 12.01
Debt/FCF 18.53
Altman-Z 0.09
ROIC/WACCN/A
WACC6.83%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 7.47 indicates that SKIN has no problem at all paying its short term obligations.
SKIN has a better Current ratio (7.47) than 97.14% of its industry peers.
SKIN has a Quick Ratio of 6.43. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.43, SKIN belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.47
Quick Ratio 6.43
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

SKIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -231.05%.
The Revenue for SKIN has decreased by -17.97% in the past year. This is quite bad
SKIN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.72% yearly.
EPS 1Y (TTM)-231.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)-17.97%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-14.5%

3.2 Future

SKIN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.03% yearly.
SKIN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.35% yearly.
EPS Next Y-43.09%
EPS Next 2Y-4.43%
EPS Next 3Y1.03%
EPS Next 5YN/A
Revenue Next Year-11.56%
Revenue Next 2Y-3.31%
Revenue Next 3Y-1.73%
Revenue Next 5Y13.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SKIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, SKIN is valued cheaply inside the industry as 94.29% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.8
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.43%
EPS Next 3Y1.03%

More info and screens

0

5. Dividend

5.1 Amount

SKIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (6/20/2025, 8:00:02 PM)

After market: 1.64 +0.03 (+1.86%)

1.61

+0.15 (+10.27%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners83.14%
Inst Owner Change-5.23%
Ins Owners9.8%
Ins Owner Change19.16%
Market Cap202.88M
Analysts49.23
Price Target1.74 (8.07%)
Short Float %7.38%
Short Ratio9.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.46%
Min EPS beat(2)27.04%
Max EPS beat(2)37.88%
EPS beat(4)4
Avg EPS beat(4)46.92%
Min EPS beat(4)20.82%
Max EPS beat(4)101.96%
EPS beat(8)8
Avg EPS beat(8)63.51%
EPS beat(12)11
Avg EPS beat(12)133.67%
EPS beat(16)13
Avg EPS beat(16)27.18%
Revenue beat(2)2
Avg Revenue beat(2)6.36%
Min Revenue beat(2)5.78%
Max Revenue beat(2)6.94%
Revenue beat(4)3
Avg Revenue beat(4)1.85%
Min Revenue beat(4)-9.83%
Max Revenue beat(4)6.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.47%
Revenue beat(12)7
Avg Revenue beat(12)1.79%
Revenue beat(16)11
Avg Revenue beat(16)5.46%
PT rev (1m)8.57%
PT rev (3m)-0.39%
EPS NQ rev (1m)23.4%
EPS NQ rev (3m)-5.5%
EPS NY rev (1m)0%
EPS NY rev (3m)5.83%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-6.85%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)-13.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.63
P/FCF 6.8
P/OCF 5.64
P/B 4.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)0.24
FCFY14.71%
OCF(TTM)0.29
OCFY17.74%
SpS2.56
BVpS0.37
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.72%
ROE -83.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.52%
FCFM 9.26%
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 12.01
Debt/FCF 18.53
Debt/EBITDA N/A
Cap/Depr 22.94%
Cap/Sales 1.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.47
Quick Ratio 6.43
Altman-Z 0.09
F-Score6
WACC6.83%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-231.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-43.09%
EPS Next 2Y-4.43%
EPS Next 3Y1.03%
EPS Next 5YN/A
Revenue 1Y (TTM)-17.97%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-14.5%
Revenue Next Year-11.56%
Revenue Next 2Y-3.31%
Revenue Next 3Y-1.73%
Revenue Next 5Y13.35%
EBIT growth 1Y52.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.82%
EBIT Next 3Y32.86%
EBIT Next 5Y34.66%
FCF growth 1Y129.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y144.35%
OCF growth 3YN/A
OCF growth 5YN/A